MBX Biosciences, Inc.

MBX Nasdaq CIK: 0001776111

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 11711 N. MERIDIAN STREET, CARMEL, IN, 46032
Mailing Address 11711 N. MERIDIAN STREET, CARMEL, IN, 46032
Phone 3179893100
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
3 Initial insider ownership report March 18, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
10-K Annual financial report March 12, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
8-K Current report of material events February 27, 2026 View on SEC
4 Insider stock transaction report February 27, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 11, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 10, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Successful IPO and secondary offering raised $205 million in net proceeds, significantly bolstering cash reserves.
  • Strong liquidity position with $165.5 million in cash, cash equivalents, and marketable securities at year-end 2025, providing a cash runway into late 2027.
View Analysis

Insider Trading

BUY 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.